SOTIO Biotech

Executive Summary

SOTIO Biotech is a Czech Republic-based pre-clinical oncology company focused on developing next-generation immunotherapies for solid tumors. Founded in 2010, the company's pipeline includes internally developed and in-licensed IL-15 superagonists and antibody-drug conjugates (ADCs), designed to enhance anti-tumor immune responses while minimizing toxicity. With a mission to deliver safer and more effective cancer treatments, SOTIO is leveraging its expertise in biologics and cell & gene therapy to advance novel candidates toward clinical development. The company is privately held and operates out of Prague, positioning itself as an emerging player in the European biotech landscape. As a pre-clinical entity, SOTIO's near-term milestones revolve around advancing its lead programs into the clinic. Key upcoming events include potential Investigational New Drug (IND) or equivalent regulatory filings for its most advanced IL-15 superagonist and ADC candidates, expected within the next 12–18 months. Additionally, the company may seek strategic partnerships to co-develop or license its technologies, and it could present promising preclinical data at major oncology conferences later this year. With no disclosed financing rounds, SOTIO's ability to execute will depend on securing additional funding or partnerships to support its pipeline progression.

Upcoming Catalysts (preview)

• Q3 2026IND filing for lead IL-15 superagonist candidate60% success
• Q3 2026Preclinical data presentation at ASCO or SITC 202680% success
• Q4 2026Strategic partnership or licensing deal for ADC platform40% success